Lanreotide Dosage

This dosage information may not include all the information needed to use Lanreotide safely and effectively. See additional information for Lanreotide.

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Geriatric Dose for:

Additional dosage information:

Usual Adult Dose for Acromegaly

Initial dose: lanreotide depot 90 mg given via the deep subcutaneous route, at 4 week intervals for 3 months

Usual Geriatric Dose for Acromegaly

Initial dose: lanreotide depot 90 mg given via the deep subcutaneous route, at 4 week intervals for 3 months

It is not necessary to alter the starting dose in elderly patients as expected lanreotide serum concentrations in the elderly are well within the range of serum concentrations safely tolerated in healthy young subjects. Similarly, it is not necessary to alter the titration or maintenance doses as dose selection is based on therapeutic response.

Renal Dose Adjustments

Moderate and Severe Renal Impairment
Starting dose: 60 mg via the deep subcutaneous route, at 4 week intervals for 3 months followed by dose adjustments as needed

Liver Dose Adjustments

Moderate and Severe Hepatic Impairment
Starting dose: 60 mg via the deep subcutaneous route, at 4 week intervals for 3 months followed by dose adjustments as needed

Dose Adjustments

The goal of treatment in acromegaly is to reduce growth hormone (GH) and insulin growth factor-1 (IGF-1) levels to normal.

After 3 months, dosage may be adjusted as follows:
GH greater than 1 to less than or equal to 2.5 ng/mL, IGF-1 normal and clinical symptoms controlled: maintain dose at 90 mg every 4 weeks.

GH greater than 2.5 ng/mL, IGF-1 elevated and/or clinical symptoms uncontrolled, increase dose to 120 mg every 4 weeks.

GH less than or equal to 1 ng/mL, IGF-1 normal and clinical symptoms controlled: reduce dose to 60 mg every 4 weeks.

Thereafter, the dose should be adjusted according to the response of the patient as judged by a reduction in serum GH and /or IGF-1 levels; and/or changes in symptoms of acromegaly.

Precautions

Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).

Dialysis

There are no dosing recommendations specifically stated as being for dialysis patients. However, the following is recommended for patients with moderate to severe renal impairment:
Starting dose: 60 mg via the deep subcutaneous route, at 4 week intervals for 3 months followed by dose adjustments as needed

Other Comments

Lanreotide should be injected via the deep subcutaneous route in the superior external quadrant of the buttock. The skin should not be folded and the needle should be inserted perpendicular to the skin, rapidly and to its full length. The injection site should alternate between the right and left side.

Advanced Breast Cancer: Learn about treatments to improve quality of life. Click Here

Close
Hide
(web2)